News

The report recommends biomedical scientists avoid general search engines and vendor catalogue information and instead use two kinds of online resource.

The drug works by targeting the interleukin-6 receptor, a potential key driver of neuromyelitis optica spectrum disorder.

The PARP inhibitor is now the first and only of its kind in the UK to be approved in all lines of maintenance treatment.

The project puts an emphasis on the integrity and security of patient data, an important topic at the moment.

The impressive achievements in pharmaceutical marketing excellence were recognised at PMLiVE’s annual PMEAs at the Royal Lancaster London Hotel, with the exciting introduction of a new award for 2019.

The decision is based on positive results from the Phase III CASPIAN trial, in which the drug increased overall survival.

However, Brexit and competition from countries like USA, Germany and Japan are cited as reasons the UK can’t seem to hold its competitive edge globally.

The information makes it “impossible to see how the original target for 5,000 extra GPs could be met by 2020”.

The boom is thanks in part to a change in the funding landscape, expressed in a four-fold increase to £2.8 billion of investment in early-stage ventures.

Avion is set to fund a new international Phase III trial with costs up to $25 million.

As many as 3,200 women in England living with advanced HR+, HER2- breast cancer will now be eligible for the treatment.

A 10% increase in vaccination may be associated with as much as a 10% fall in sickness absence.

The CGT Catapult has released its latest Good Manufacturing Practice report and skills demand report.

Lack of sleep can induce flare-ups, creating a vicious cycle and putting patients at risk of serious additional health challenges.

The news comes shortly after a YouGov poll found that 81% of HCPs think that general analysis of data would help enable quicker diagnosis and more effective treatment.